"Dr. Michael Weitz Dr. Jeffrey Ritter Dr. Santiago de Solo Dr. Joseph LaConti Carrie Herzog, PA-C"

During the past decade, Center for Arthritis and Rheumatic Diseases conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 12 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Arthritis and Rheumatic Diseases" #1 sponsor was "Pfizer" with 7 trials, followed by "Janssen Research & Development, LLC" with 2 trials sponsored, "Shire" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "DePuy Mitek" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Arthritis and Rheumatic Diseases" #1 collaborator was "Oregon Health and Science University" with 1 trials as a collaborator and "The Cleveland Clinic" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Center for Arthritis and Rheumatic Diseases" are "Rheumatoid Arthritis" (5 trials), "Arthritis, Rheumatoid" (4 trials), "Arthritis, Psoriatic" (2 trials), "Osteoarthritis, Hip" (2 trials) and "Osteoarthritis, Knee" (2 trials). Many other conditions were trialed in "Center for Arthritis and Rheumatic Diseases" in a lesser frequency.

Most popular intervention types in "Center for Arthritis and Rheumatic Diseases" are "Drug" (16 trials), "Biological" (3 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "CP-690,550" (3 trials), "Guselkumab" (2 trials), "Tanezumab 2.5 mg" (2 trials) and "Tanezumab 5 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Center for Arthritis and Rheumatic Diseases" are 15 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Center for Arthritis and Rheumatic Diseases". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Center for Arthritis and Rheumatic Diseases, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Arthritis and Rheumatic Diseases, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".

Center for Arthritis and Rheumatic Diseases has several departments that took part in Clinical trials: "Center For Arthritis; Research Dept" - 3 trials